LHYFE Fundamental Analysis - LHYFE SAS

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to LHYFE. LHYFE was compared to 67 industry peers in the Oil, Gas & Consumable Fuels industry. LHYFE may be in some trouble as it scores bad on both profitability and health. LHYFE is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

LHYFE had negative earnings in the past year.

LHYFE had a negative operating cash flow in the past year.

In the past 5 years LHYFE always reported negative net income.

In the past 5 years LHYFE always reported negative operating cash flow.

1.2 Ratios

LHYFE has a worse Return On Assets (-15.61%) than 89.55% of its industry peers.

LHYFE has a worse Return On Equity (-72.55%) than 91.04% of its industry peers.

		Industry Rank	Sector Rank
ROA	-15.61%
ROE	-72.55%
ROIC	N/A

ROA(3y)-14.84%

ROA(5y)-14.98%

ROE(3y)-30.65%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of LHYFE (80.73%) is better than 86.57% of its industry peers.

LHYFE's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for LHYFE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	80.73%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y97.82%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LHYFE does not have a ROIC to compare to the WACC, probably because it is not profitable.

LHYFE has about the same amout of shares outstanding than it did 1 year ago.

LHYFE has more shares outstanding than it did 5 years ago.

LHYFE has a worse debt/assets ratio than last year.

2.2 Solvency

LHYFE has an Altman-Z score of -0.51. This is a bad value and indicates that LHYFE is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of LHYFE (-0.51) is worse than 85.07% of its industry peers.

A Debt/Equity ratio of 1.55 is on the high side and indicates that LHYFE has dependencies on debt financing.

LHYFE has a Debt to Equity ratio of 1.55. This is amonst the worse of the industry: LHYFE underperforms 82.09% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.55
Debt/FCF	N/A
Altman-Z	-0.51

ROIC/WACCN/A

WACC7.35%

2.3 Liquidity

LHYFE has a Current Ratio of 1.69. This is a normal value and indicates that LHYFE is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 1.69, LHYFE is in the better half of the industry, outperforming 71.64% of the companies in the same industry.

A Quick Ratio of 1.69 indicates that LHYFE should not have too much problems paying its short term obligations.

LHYFE has a better Quick ratio (1.69) than 77.61% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.69
Quick Ratio	1.69

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

LHYFE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.67%.

Looking at the last year, LHYFE shows a very strong growth in Revenue. The Revenue has grown by 209.99%.

The Revenue has been growing by 195.81% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-16.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-55.17%

Revenue 1Y (TTM)209.99%

Revenue growth 3Y195.81%

Revenue growth 5YN/A

Sales Q2Q%177.45%

3.2 Future

The Earnings Per Share is expected to grow by 14.11% on average over the next years. This is quite good.

The Revenue is expected to grow by 129.95% on average over the next years. This is a very strong growth

EPS Next Y-5.47%

EPS Next 2Y14.17%

EPS Next 3Y14.11%

EPS Next 5YN/A

Revenue Next Year111.33%

Revenue Next 2Y290.88%

Revenue Next 3Y183.6%

Revenue Next 5Y129.95%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LHYFE. In the last year negative earnings were reported.

Also next year LHYFE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as LHYFE's earnings are expected to grow with 14.11% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y14.17%

EPS Next 3Y14.11%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

LHYFE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

LHYFE SAS

EPA:LHYFE (12/30/2025, 9:03:22 AM)

2.835

+0.04 (+1.25%)

Chartmill FA Rating

GICS SectorEnergy

GICS IndustryGroupEnergy

GICS IndustryOil, Gas & Consumable Fuels

Earnings (Last)09-30 2025-09-30

Earnings (Next)N/A N/A

Inst Owners8.67%

Inst Owner ChangeN/A

Ins Owners21.31%

Ins Owner ChangeN/A

Market Cap136.31M

Revenue(TTM)8.07M

Net Income(TTM)-37.00M

Analysts84

Price Target4.08 (43.92%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-20.4%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-17.96%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-52.82%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	16.9
P/FCF	N/A
P/OCF	N/A
P/B	2.73
P/tB	4.7
EV/EBITDA	N/A

EPS(TTM)-0.77

EYN/A

EPS(NY)-0.55

Fwd EYN/A

FCF(TTM)-1.12

FCFYN/A

OCF(TTM)-0.48

OCFYN/A

SpS0.17

BVpS1.04

TBVpS0.6

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-15.61%
ROE	-72.55%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	80.73%
FCFM	N/A

ROA(3y)-14.84%

ROA(5y)-14.98%

ROE(3y)-30.65%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y97.82%

GM growth 5YN/A

F-Score4

Asset Turnover0.03

Health

		Industry Rank	Sector Rank
Debt/Equity	1.55
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	475.46%
Cap/Sales	384.33%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.69
Quick Ratio	1.69
Altman-Z	-0.51

F-Score4

WACC7.35%

ROIC/WACCN/A

Cap/Depr(3y)952.98%

Cap/Depr(5y)2679.39%

Cap/Sales(3y)1914.48%

Cap/Sales(5y)13335.5%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-16.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-55.17%

EPS Next Y-5.47%

EPS Next 2Y14.17%

EPS Next 3Y14.11%

EPS Next 5YN/A

Revenue 1Y (TTM)209.99%

Revenue growth 3Y195.81%

Revenue growth 5YN/A

Sales Q2Q%177.45%

Revenue Next Year111.33%

Revenue Next 2Y290.88%

Revenue Next 3Y183.6%

Revenue Next 5Y129.95%

EBIT growth 1Y-13.06%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year19.36%

EBIT Next 3Y31.11%

EBIT Next 5Y27.12%

FCF growth 1Y-63.98%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-23.34%

OCF growth 3YN/A

OCF growth 5YN/A

LHYFE SAS / LHYFE.PA FAQ

Can you provide the ChartMill fundamental rating for LHYFE SAS?

ChartMill assigns a fundamental rating of 2 / 10 to LHYFE.PA.

Can you provide the valuation status for LHYFE SAS?

ChartMill assigns a valuation rating of 0 / 10 to LHYFE SAS (LHYFE.PA). This can be considered as Overvalued.

What is the profitability of LHYFE stock?

LHYFE SAS (LHYFE.PA) has a profitability rating of 1 / 10.

What is the financial health of LHYFE SAS (LHYFE.PA) stock?

The financial health rating of LHYFE SAS (LHYFE.PA) is 2 / 10.

LHYFE SAS (LHYFE.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

LHYFE SAS / LHYFE.PA FAQ

Can you provide the ChartMill fundamental rating for LHYFE SAS?

Can you provide the valuation status for LHYFE SAS?

What is the profitability of LHYFE stock?

What is the financial health of LHYFE SAS (LHYFE.PA) stock?